[{"id":"856ad1d8-bfdb-472d-854a-1ee9dbe97a1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02656147","created_at":"2021-01-18T12:55:28.090Z","updated_at":"2024-07-02T16:37:18.182Z","phase":"Phase 1","brief_title":"Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL","source_id_and_acronym":"NCT02656147","lead_sponsor":"Beijing Doing Biomedical Co., Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gamma delta T-cells • anti-CD19-CAR γδT"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2017","start_date":" 10/01/2017","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2017-09-05"}]